## Pharmacy Prior Authorization

## AETNA BETTER HEALTH FLORIDA

Xermelo (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Florida at 1-855-799-2554.

When conditions are met, we will authorize the coverage of Xermelo (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug	Name (circle drug)				
Xerm	elo (telotristat ethyl)				
Other	, specify drug				
Quantity Route of administration		Frequency	Strength		
		Expected length of therapy			
Patie Patie	nt ID:				
	nt phone:				
Pres	cribing physician				
Physi	ician name:				
Specialty:		NPI number:			
Physician fax:		Physician phone:			
Physi	ician address:	City, state, zip:			
Diag	nosis:	ICD Code:			
Circle	the appropriate answer for ea	ach question.			
1.	Does the patient have a cometastatic neuroendocrin	diagnosis of carcinoid syndrome diarrheane tumors?	ı with	Y	N
	[If no, no further question	ns.]			
2.	Is the patient 18 years of	age or older?		Υ	N
	[If no, no further question	ns.]			
3.	,	to assess the patient for severe constipa discontinue the medication if either deve		Y	N
	[If no, no further question	ns.]			

Reference Number: C12388-A / Effective Date: 03/24/2018

Pre	scriber (Or Authorized) Signature D	ate					
affirm that the information given on this form is true and accurate as of this date.							
Comments:							
7.	Has the patient experienced a reduction from baseline in amount of average daily bowel movements per day?	Υ	N				
	[No further questions]						
6.	Will Xermelo be used in combination with SSA therapy?	Υ	N				
	[If no, no further questions.]						
5.	Has the patient had a trial and inadequate response to the maximum (or highest tolerated) dose of somatostatin analog (SSA) therapy (inadequate response is at least four or more bowel movements daily) for at least three consecutive months?	Υ	N				
	[If yes, skip to question 7.]						
4.	Is the request for continuation of therapy?	Υ	N				

Reference Number: C12388-A / Effective Date: 03/24/2018